Dyadic International, Inc.

Dyadic International (NASDAQ: DYAI - Get Free Report) and Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk. Profitability This table compares Dyadic International and

Dyadic International (NASDAQ: DYAI) is moving from technology-platform development toward commercial execution, with multiple products entering the market through its own channels and partnerships, President and Chief Operating Officer Joe Hazelton said at the Lytham Partners Fall 2026 Investor Conference. Hazelton said the company is applying its fungal gene-expression platforms to produce proteins and enzymes for

Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) and Dyadic International (NASDAQ: DYAI - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability. Volatility and Risk Amylyx Pharmaceuticals has a beta

Dyadic International Inc. (NASDAQ: DYAI - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.72 and traded as low as $0.4351. Dyadic International shares last traded at $0.4660, with a volume of 116,708 shares trading hands. Analyst Upgrades and